Literature DB >> 17488680

Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Raffaella Origa1, Renzo Galanello, Tomas Ganz, Nicolina Giagu, Liliana Maccioni, Gavino Faa, Elizabeta Nemeth.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with beta-thalassemia, like those with genetic hemochromatosis, develop iron overload due to increased iron absorption, and their iron burden is further exacerbated by transfusion therapy. Hepcidin, a hepatic hormone, regulates systemic iron homeostasis by inhibiting the absorption of iron from the diet and the recycling of iron by macrophages. In turn, hepcidin release is increased by iron loading and inhibited by erythropoietic activity. Hepcidin deficiency is the cause of iron overload in most forms of hereditary hemochromatosis. We sought to determine hepcidin's role in the pathogenesis of iron overload in b-thalassemia. DESIGN AND METHODS: We assessed the degree of iron overload in thalassemia intermedia and major patients by measuring hepatic iron concentration in liver biopsy samples and serum ferritin, estimated erythropoietic drive by assaying soluble transferrin receptor and serum erythropoietin levels and correlated these with urinary hepcidin measurements.
RESULTS: Urinary hepcidin levels in beta-thalassemia demonstrate severe hepcidin deficiency in thalassemia intermedia. There was a strong inverse relationship between urinary hepcidin levels and both erythropoietin and soluble transferrin receptor, markers of erythropoietic activity. In contrast, hepcidin levels were elevated in thalassemia major, presumably due to transfusions that reduce erythropoietic drive and deliver a large iron load. Despite similar liver iron concentrations in the two conditions, serum ferritin was much lower in thalassemia intermedia. INTERPRETATION AND
CONCLUSIONS: In thalassemia intermedia, high erythropoietic drive causes severe hepcidin deficiency. The lack of hepcidin results in hyperabsorption of dietary iron, but also in iron depletion of macrophages, lowering their secretion of ferritin and, consequently, serum ferritin levels. In contrast, in thalassemia major, transfusions decrease erythropoietic drive and increase the iron load, resulting in relatively higher hepcidin levels. In the presence of higher hepcidin levels, dietary iron absorption is moderated and macrophages retain iron, contributing to higher serum ferritin. In the future, hepcidin measurements may allow a more accurate assessment of the degree of iron overload and the maldistribution of iron in thalassemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488680     DOI: 10.3324/haematol.10842

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  123 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 3.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

Review 4.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

Review 5.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

6.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

7.  Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia.

Authors:  Erik R Anderson; Matthew Taylor; Xiang Xue; Sadeesh K Ramakrishnan; Angelical Martin; Liwei Xie; Bryce X Bredell; Sara Gardenghi; Stefano Rivella; Yatrik M Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 8.  Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

Authors:  Wai Cheng Foong; Jacqueline J Ho; C Khai Loh; Vip Viprakasit
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

Review 9.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

10.  Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.

Authors:  Jason S Troutt; Anthony M Butterfield; Robert J Konrad
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.